EL7.AI
StocksMediumUpdated•Originally published 14 September 2026•Updated 14 September 2026•
2 min read

Moderna-Merck AI-Assisted Melanoma Therapy Meets Phase 3 Endpoints

Key Facts

1Intismeran autogene plus KEYTRUDA met the recurrence-free and distant metastasis-free survival endpoints in Phase 3.
2INTerpath-001 enrolled 1,137 patients and randomized them 2:1.
3The design process uses AI algorithms to select up to 34 neoantigens.
4The therapy remains investigational, and overall-survival follow-up continues.

Moderna and Merck said on August 19, 2026 that individualized mRNA therapy intismeran autogene, combined with KEYTRUDA, met the primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival in the Phase 3 INTerpath-001 trial. The study involved patients with completely resected stage IIB-IV cutaneous melanoma.

The result came from a prespecified interim analysis, with the companies reporting statistically significant and clinically meaningful improvements versus KEYTRUDA alone. The topline announcement did not provide numerical effect estimates, so the magnitude of benefit and differences across patient groups cannot yet be assessed from the disclosure alone.

The global, randomized, double-blind trial enrolled 1,137 patients and assigned them 2:1 to intismeran autogene plus KEYTRUDA or KEYTRUDA alone. The primary endpoint measures the time from randomization to disease recurrence or death from any cause.

Personalizing intismeran autogene begins with genetic-sequencing data from tumor and blood samples. Moderna uses AI algorithms to review mutations and predict up to 34 neoantigens considered likely to elicit an immune response, after which the selected neoantigens are encoded in a patient-specific mRNA strand.

Patients in the combination group received 1 mg of intismeran autogene every 3 weeks for up to 9 doses, alongside 400 mg of KEYTRUDA every 6 weeks for up to 9 cycles. Treatment continued until recurrence, unacceptable toxicity or a total duration of about 56 weeks.

The companies said the combination's safety profile was consistent with earlier studies and showed no new safety signals. Intismeran autogene nevertheless remains investigational: meeting trial endpoints is not regulatory approval, and the study continues to evaluate overall survival and other secondary endpoints.

The companies plan to present detailed Phase 3 data at an international medical meeting and discuss filing submissions with regulators. For investors, the result strengthens the therapy's clinical case, but its commercial path will still depend on the full effect estimates, follow-up results and regulatory decisions.